DG
CMMB

Delek Group’s Chemomab Therapeutics CMMB Stock Holding History

Delek Group’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$114K Hold
408
– – ﹤0.01% 220
2019
Q1 		$176K Buy
+408
New +$206K 0.01% 201

Other funds holding CMMB

MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Delek Group's CMMB Position: Q2 2019 in Review

Delek Group held its Chemomab Therapeutics (CMMB) position steady in Q2 2019 at 408 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #220.

Delek Group first reported a position in CMMB in Q1 2019 and has held it in 2 quarters since. The position peaked at $176K in Q1 2019. 9 funds tracked by Wall St. Rank hold CMMB as of Q2 2019.

  • Delek Group held 408 shares of Chemomab Therapeutics worth $114K as of Q2 2019.
  • Delek Group left its Chemomab Therapeutics share count unchanged in Q2 2019.
  • Chemomab Therapeutics made up ﹤0.01% of Delek Group's portfolio in Q2 2019, its #220 holding.
  • Delek Group first reported a position in Chemomab Therapeutics in Q1 2019 and has held it in 2 quarters since.
  • Delek Group's Chemomab Therapeutics position peaked at $176K in Q1 2019.
  • 9 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.